Biogen Inc.
XETRA: IDP.DE0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Deutsche Börse
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Christopher A. Viehbacher
- Employees
- 7,605
- Headquarters
- Cambridge, United States
- IPO year
- 2000
- Market cap
- €24.2B
- Website
- https://www.biogen.com
Loading IDP…
Loading profile data…Frequently asked questions about IDP
What does Biogen Inc. (IDP.DE) do?
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
Where does IDP.DE trade?
Biogen Inc. (IDP.DE) trades on the Deutsche Börse.
What sector is IDP.DE in?
Biogen Inc. (IDP.DE) operates in the Healthcare sector, specifically in the Drug Manufacturers - General industry.
Who is the CEO of Biogen Inc.?
Christopher A. Viehbacher is the chief executive officer of Biogen Inc. (IDP.DE).
Where is Biogen Inc. headquartered?
Biogen Inc. is headquartered in United States.
Does IDP.DE pay a dividend?
Biogen Inc. (IDP.DE) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did IDP.DE go public?
Biogen Inc. (IDP.DE) completed its initial public offering in 2000.